Oncology/Cancer Drugs Market - Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Oncology/Cancer Drugs Market - Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

Description:

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. – PowerPoint PPT presentation

Number of Views:143

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Oncology/Cancer Drugs Market - Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020


1
Global Oncology/Cancer Drugs Market Forecast
2013 - 2020
Published Date 24 February 2015 No. of
pages 159
2
 
Introduction to Oncology/Cancer Drugs Market
Biological drugs based on monoclonal antibodies
(mAbs) have emerged as a preferred option for
treating various cancer types, especially for
blood cancer (leukemia). Rising incidence of
various cancer conditions, growing popularity of
advance therapies (biological and targeted drug
therapies), patents expiration of leading drugs
along with commercialization of biosimilars are
the few factors driving the growth of global
oncology drugs market. However, high cost
involved in new drug development coupled with
threat of failure and adverse effects associated
with cancer drugs therapies would restrain the
growth of the market. Commercialization of
advanced therapeutics such as targeted and
immunotherapies would reduce the negative
influence of restraints and fuel the market
growth. The global oncology drugs market is
expected to reach at 111.9 billion by 2020.
Patent expiration of key cancer drugs such as
Herceptin, Erbitux, Rituxan and Avastin, is
expected to boost the growth of cancer
biosimilars market by 2020. Going further, the
biological therapies are expected to dominate the
market by 2020, due to their high efficacy,
target specific action and less toxicity. Blood
cancer drugs market was the largest revenue
generating segment in 2013 owing to the high cost
of drugs (immunotherapies) used for the treatment
of blood cancer. Geographically, North America,
dominates the market followed by Europe. North
America accounted for about 38 share in the
overall oncology drugs market in 2013 owing to
the heavy investments by multinational companies
in research and development of cancer drugs,
particularly immune therapeutics, favorable
reimbursement policies, and high adoption rate of
immunotherapies. On the other hand, Asia-Pacific
market would grow at the promising CAGR of 8.7
during the forecast period.
3
 
Introduction
Scope of the Report
Key Benefits
Key Audiences
4
 
KEY BENEFITS
  • The report provides the quantitative analysis of
    the current market and estimations through
    2013-2020 that assists in identifying the
    prevailing market opportunities to capitalize on
  • The report helps in understanding the strategies
    adopted by various companies for gaining market
    share in the cancer drugs market
  • The report provides comprehensive analysis of
    factors that drive and restrict the growth of the
    cancer drugs market
  • Market conditions of cancer drugs market across
    all geographic regions are comprehensively
    analysed
  • Competitive intelligence (of leading
    manufacturers) helps in understanding the
    competitive scenario across the geographies
  • SWOT analysis of the key market players is
    provided to illustrate the business strategies
    adopted by the companies

5
 
Table of Contents
  1.  INTRODUCTION
  2. EXECUTIVE SUMMARY
  3. MARKET OVERVIEW
  4. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY
    THERAPEUTIC MODALITIES
  5. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER
    TYPES
  6. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY
  7. COMPANY PROFILES

6
 
Global Oncology/Cancer Drugs Market Overview
  1. Market Definition Scope
  2. Development of novel immuno-oncology drug
    products
  3. Key findings
  4. Porters five forces analysis
  5. Value chain analysis
  6. Government regulations and reimbursement
  7. Patent analysis
  8. Market share analysis, 2013
  9.  Clinical trials for oncology drugs
  10. Market dynamics

7
 
 Global Oncology/Cancer Drugs Market By
Therapeutic Modalities
8
 
Global Oncology/Cancer Drugs Market By Cancer
Types
9
 
Global  Oncology/Cancer Drugs Market By Geography
 North America, Europe, Asia Pacific, LAMEA
10
 
Company Profiles
  1. Amgen Inc.
  2. Johnson and Johnson
  3. Roche Diagnostics
  4. GlaxoSmithKline PLC
  5. Merck Company
  6. Novartis AG
  7.  Pfizer
  8. Sanofi
  9. Eli Lilly and Company
  10.  Celgene Corporation

11
 
Thank You! For More Details
Visit us at
http//www.alliedmarketresearch.com/oncology-cance
r-drugs-market
Follow Us On
About PowerShow.com